title: Everolimus.
authors: Beth Israel Deaconess Medical Center, 375 Longwood Avenue, MS-413, Boston, Massachusetts 02215, USA. matkins@bidmc.harvard.edu
authors: Michael B
authors: MB
authors: Atkins
authors: Uma
authors: U
authors: Yasothan
authors: Peter
authors: P
authors: Kirkpatrick
mesh_terms: D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D055808:Drug Discovery; D000068338:Everolimus; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D011494:Protein Kinases / Q000502:physiology; D015398:Signal Transduction; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
chemical_list: D042461:Vascular Endothelial Growth Factor A; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus